An interventional study of Dexcom G7 rtCGM and Capillary Blood glucose Testing (POC) in Type 1 Diabetes, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Emory University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 1 by Emory University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Emory University.
Among the 14 studies in Diabetes Mellitus, Type 1 by Emory University, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →5 of the 14 studies in Diabetes Mellitus, Type 1 by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
Emory University · Sites in United States
Ages 65+
Emory University · Sites in United States
Ages 18+
Emory University · Sites in United States
Ages 18–40
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 2 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 24 across the 13 interventional studies, 44 across the 1 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT06448429Emory UniversityTesting an Integrated Care Model Trial | 2027-02 |
| NCT07474376Emory UniversityDiabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 1 by Emory University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to compare inpatient glycemic control by measuring the percentage of time in the range of 70-180 mg/dl and the frequency of hypoglycemia between Dexcom G7 Continuous Glucose Monitoring (CGM) and Point of Care (POC) Blood Glucose Testing in poorly controlled subjects with Type 1 Diabetes Mellitus.
The main question it aims to answer is:
-Whether there is a difference between POC testing (standard of care) and Real-time CGM in glycemic control and hypoglycemic events during hospitalization:
The CDC reports that 1.6 million U.S. adults (5.7%) have type 1 diabetes (T1D), with hospitalization rates three times higher than the general population, primarily due to diabetes-related complications such as ketoacidosis and cardiovascular disease. A study at Emory University found that hospitalized T1D patients are younger, experience longer stays and more admissions, and face worse glycemic control and higher rates of hypoglycemia compared to type 2 diabetes (T2D) patients.
Point-of-care (POC) capillary glucose testing is the standard for monitoring hospitalized diabetes patients, but continuous glucose monitoring (CGM) offers more detailed glycemic profiles. Research, including trials using Dexcom CGM systems, has demonstrated CGM's superior ability to detect hypo- and hyperglycemia, reduce hypoglycemic events, and improve insulin therapy adjustments in T2D patients. However, no randomized controlled studies have evaluated the best glucose monitoring system for hospitalized T1D patients.
The proposed study aims to compare POC testing with Dexcom G7 CGM for guiding insulin therapy in hospitalized T1D patients. Researchers hypothesize that CGM will better prevent hypoglycemia and improve glycemic management during hospital stays, addressing a critical gap in evidence regarding glucose control's impact on T1D hospital outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) with intravenous or subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded to the electronic medical record (EMR) system. The research team, together with the Primary care (PCP) team, will adjust daily insulin orders based on POC readings (standard of care). In addition, subjects will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, medicine, or research teams) during hospitalization for up to 10 days.
Diagnostic Test: Capillary Blood glucose Testing (POC)
Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) intravenously with subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Subjects will wear a real-time Dexcom G7 CGM for up to 10 days. Insulin therapy will be titrated based on daily CGM reports, including mean glucose, glycemic excursions, hypoglycemia, and severe hyperglycemia \> 180 and \>250 mg/dl values. Participants will wear a Dexcom rtCGM for up to 10 days during hospitalization.
Device: Dexcom G7 rtCGM
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 CGM System or G7) is a glucose monitoring system that continuously measures glucose in the interstitial fluid. It aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments
POC glucose meters measure whole blood and convert the results to plasma glucose concentrations, which is the standardized form used in clinical practice.
Also known as: POCT (point of care therapy)
Glycemic control
The total difference in blood sugar levels between the POC testing (standard of care) group and the rtCGM group throughout the hospitalization
Time frame: Through study completion (Day 10 or the length of admission)
Clinically significant hypoglycemia <54 mg/dl
The difference between blood sugar levels in POC testing (standard of care) group and rtCGM group during hospitalization
Time frame: Through study completion (Day 10 or the length of admission)
Time above range
% time above Target Above range (TAR). Differences between the both groups will be calculated. (TAR, \>250 mg/dl)
Time frame: Through study completion (Day 10 or the length of admission)
Time below range
% time in Below Target range (TBR). Differences between the both groups will be calculated. Differences between the both groups will be calculated. (TBR, \< 70 and 54 mg/dl)
Time frame: Through study completion (Day 10 or the length of admission)
Glycemic Variability [% Coefficient of Variation (%CV)
% coefficient of variation will be measured during the intervention phase, compared to control, as measured by CGM.
Time frame: Through study completion (Day 10 or the length of admission)
Hypoglycemic events
Number of hypoglycemia events \< 70 and 54 mg/dl
Time frame: Through study completion (Day 10 or the length of admission)
Hyperglycemic events
Number of hypoglycemia events \>250 mg/dl
Time frame: Through study completion (Day 10 or the length of admission)
Nocturnal hypoglycemia
Number of hypoglycemic events (\<70 and \<54 mg/dl) between 22:00 and 06:00
Time frame: Through study completion (Day 10 or the length of admission)
Prolonged hypoglycemia
Number of events of Prolonged hypoglycemia \< 70 mg/dl for more than 2 hours by CGM
Time frame: Through study completion (Day 10 or the length of admission)
Hospital Complications
Hospital complications include a composite of acute kidney injury (doubling of serum creatinine \>0.5 mg/dl from baseline), cardiovascular events, infections, and death
Time frame: Through study completion (Day 10 or the length of admission)
Recurrent hypoglycemia
Number of recurrent hypoglycemic episodes (\< 70 mg/dl)
Time frame: Through study completion (Day 10 or the length of admission)
Recurrent hyperglycemia
Number of recurrent hyperglycemic episodes (\>250 mg/dl)
Time frame: Through study completion (Day 10 or the length of admission)
Clinically significant hypoglycemia
Number of clinically significant hypoglycemic episodes: \<54 mg/dl
Time frame: Through study completion (Day 10 or the length of admission)
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 17 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.